ASCO GU 2025 had groundbreaking advancements in genitourinary cancer treatments, focusing on prostate cancer, renal cell ...

Simple blood markers may predict nivolumab outcomes in metastatic renal cell carcinoma. Learn how eosinophils could help ...

For patients with oligometastatic cancers, particularly kidney or prostate, stereotactic body radiotherapy may frequently ...

Gastrointestinal metastases from primary lung adenocarcinoma are rare, with only a few reported cases of gastrointestinal bleeding caused by such metastases. Among the cancers that most commonly ...

A redesigned immune-activating cancer drug has produced striking early results in a small clinical trial, shrinking tumors ...

Prevalence of Electrolyte Disorders in Oncology: Descriptive Cross-Sectional Study in the Cancer Department of the National ...

In 2025, the FDA approved 73 first-time generic drugs.  Here are the generics and their indication, in order of approval date: Note: The FDA’s information is current as of Dec. 18. 1. Phytonadione ...

On the list of medical terms we'd rather never hear, cancer is at the top. But when it comes to fighting it, knowledge is ...

EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the ...

Pancreatic metastases are rare and frequently misdiagnosed, leaving clinicians uncertain about how to assess prognosis and select optimal treatment. In a recent large single-center retrospective study ...

Here are the top 5 stories from 2025 about the advancements in prostate, kidney, and bladder cancers.

The cellular therapy landscape continues to evolve beyond hematologic malignancies, now making significant progress in solid ...